Desvenlafaxine succinate hydrate was approved by the U.S. Food and Drug Administration (FDA) on February 29, 2008.It was developed by Pfizer, then marketed as Pristiq® by Pfizer in the US.
The exact mechanism of the antidepressant action of Desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that Desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). It is indicated for the treatment of major depressive disorder (MDD).
Pristiq® is available as extended release tablet for oral use, containing 50 mg or 100 mg of free Desvenlafaxine. The recommended dose is 50 mg once daily with or without food.
|Approval Date||Approval Type||Trade Name||Indication||Dosage Form||Strength||Company||Review Classification|
|2008-02-29||Marketing approval||Pristiq||Major depressive disorder (MDD)||Tablet, Extended release||Eq. 50 mg/100 mg Desvenlafaxine||Pfizer||Priority|
|Formula||C16H25NO2 • C4H6O4 • H2O|
93413-62-8 (Desvenlafaxine );
386750-22-7 (Desvenlafaxine Succinate Monohydrate);
|Chemical Name||RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol succinate monohydrate|
|Desvenlafaxine （Free Acid/Base）Parameters：|
|*：Calculated by ACD/Labs software V11.02.|